Covid-19: Serum Institute produces over 10 crore Covishield doses in June

Published On 2021-06-28 07:57 GMT   |   Update On 2021-06-28 07:57 GMT
Advertisement

New Delhi: Fulfilling its commitment, Serum Institute of India has produced over 10 crore doses of its Covid-19 vaccine Covishield in June so far as India ramps up the pace of its vaccination drive in the face of a possible third wave of the viral infection.

India's Covid-19 inoculation drive has picked up pace under the new phase of universalisation of Covid-19 vaccination that commenced on June 21 with around 69 lakh
Advertisement
vaccine doses
being administered on an average daily in the last six days.
The immunisation data published at 7 am on Sunday showed that India administered 64.25 lakh vaccine doses in a day, taking the cumulative number of jabs given so far under the nationwide inoculation drive to 32.17 crore.
According to information provided to the Drugs Controller General of India (DCGI) by the Pune-based Serum Institute of India, it has sent 45 batches of Covishield, amounting to 10.80 crore doses, to the Central Drugs Laboratory, Kasauli for release in June so far.
The firm's Director at Government and Regulatory Affairs, Prakash Kumar Singh, had in May communicated to Union Home Minister Amit Shah that Covishield production would be ramped up to 10 crore doses in June.
"We are committed to enhancing the production capacity of our Covishield vaccine and have been working round-the-clock in spite of various challenges being faced by us because of Covid-19 pandemic."
"We are pleased to inform that in the month of June we will be able to manufacture and supply nine to 10 crore doses of our Covishield vaccine to our country as compared to our present production capacity of 6.5 crore doses in May," Singh had said in a communication to Shah.
The nationwide vaccination drive has been ramped up through the availability of more vaccines, advance visibility of vaccine availability to states and Union Territories is enabling them to plan better, streamlining the vaccine supply chain, according to the Health Ministry.
Under the revised guidelines, vaccine doses are provided free of cost by the Centre and are allocated to states and Union Territories based on criteria such as population, disease burden and the progress of vaccination. The Centre procures 75 per cent of the vaccines being produced in the country.
All above the age of 18 years are eligible for free vaccine doses.
The Centre had earlier allowed states and private hospitals to procure 50 per cent of the vaccines following demands for decentralisation of the process. However, after several states complained of problems including funding, Prime Minister Narendra Modi announced the revised vaccine guidelines.
In order to incentivise production and encourage new vaccines, domestic manufacturers are given the option to provide vaccines directly to private hospitals. This is restricted to 25 per cent of their monthly production under the new guidelines.



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News